
    
      There will be three groups of treatment by dosage regimen in this study. Eligible subjects
      will be randomized to receive any of the following regimens: 1) DLBS1449 at a dose of 1 x 75
      mg daily, or 2) DLBS1449 at a dose of 1 x 150 mg (two capsules of DLBS1449 75 mg) daily; or
      3) placebo, once daily. Study medication should be administered once daily, in the evening
      with meal, for eight weeks. Clinical and laboratory examinations to evaluate investigational
      drug's efficacy and safety will be performed at baseline and at interval of four weeks over
      8-week course of therapy.
    
  